Clinical Psychopharmacology and Neuroscience

Korean College of Neuropsychopharmacology (대한정신약물학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review

  • Shim, In Hee (Department of Psychiatry, Cancer Center, Dongnam Institute of Radiological & Medical Sciences) ;
  • Bahk, Won-Myong (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Woo, Young Sup (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Bo-Hyun (Department of Psychiatry, Naju National Hospital)
  • Received : 2018.03.07
  • Accepted : 2018.03.12
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

We reviewed clinical studies investigating the pharmacological treatment of major depressive episodes (MDEs) with mixed features diagnosed according to the dimensional criteria (more than two or three [hypo]manic symptoms+principle depressive symptoms). We systematically reviewed published randomized controlled trials on the pharmacological treatment of MDEs with mixed features associated with mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). We searched the PubMed, Cochrane Library, and ClinicalTrials.gov databases through December 2017 with the following key word combinations linked with the word OR: (a) mixed or mixed state, mixed features, DMX, mixed depression; (b) depressive, major depressive, MDE, MDD, bipolar, bipolar depression; and (c) antidepressant, antipsychotic, mood stabilizer, anticonvulsant, treatment, medication, algorithm, guideline, pharmacological. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We found few randomized trials on pharmacological treatments for MDEs with mixed features. Of the 36 articles assessed for eligibility, 11 investigated MDEs with mixed features in mood disorders: six assessed the efficacy of antipsychotic drugs (lurasidone and ziprasidone) in the acute phase of MDD with mixed features, although four of these were post hoc analyses based on large randomized controlled trials. Four studies compared antipsychotic drugs (olanzapine, lurasidone, and ziprasidone) with placebo, and one study assessed the efficacy of combination therapy (olanzapine+fluoxetine) in the acute phase of BD with mixed features. Pharmacological treatments for MDEs with mixed features have focused on antipsychotics, although evidence of their efficacy is lacking. Additional well-designed clinical trials are needed.

Keywords

References

  1. Akiskal HS, Benazzi F. Family history validation of the bipolar nature of depressive mixed states. J Affect Disord 2003;73:113-122. https://doi.org/10.1016/S0165-0327(02)00330-0
  2. Akiskal HS, Benazzi F. Validating Kraepelin's two types of depressive mixed states: “depression with flight of ideas“and” excited depression”. World J Biol Psychiatry 2004;5:107-113. https://doi.org/10.1080/15622970410029919
  3. Benazzi F. Depressive mixed states: unipolar and bipolar II. Eur Arch Psychiatry Clin Neurosci 2000;250:249-253. https://doi.org/10.1007/s004060070014
  4. Benazzi F. Depressive mixed state: testing different definitions. Psychiatry Clin Neurosci 2001;55:647-652. https://doi.org/10.1046/j.1440-1819.2001.00919.x
  5. Benazzi F. Mixed states in bipolar II disorder: should full hypomania always be required? Psychiatry Res 2004;127:247-257. https://doi.org/10.1016/j.psychres.2003.07.006
  6. Benazzi F, Akiskal HS. Delineating bipolar II mixed states in the Ravenna-San Diego collaborative study: the relative prevalence and diagnostic significance of hypomanic features during major depressive episodes. J Affect Disord 2001;67:115-122. https://doi.org/10.1016/S0165-0327(01)00444-X
  7. Shim IH, Woo YS, Jun TY, Bahk WM. Mixed-state bipolar I and II depression: time to remission and clinical characteristics. J Affect Disord 2014;152-154:340-346. https://doi.org/10.1016/j.jad.2013.09.035
  8. Muneer A. Staging models in bipolar disorder: a systematic review of the literature. Clin Psychopharmacol Neurosci 2016;14:117-130. https://doi.org/10.9758/cpn.2016.14.2.117
  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Wasington, DC:American Psychiatric Association;2000.
  10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100. https://doi.org/10.1371/journal.pmed.1000100
  11. Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2016;173:400-407. https://doi.org/10.1176/appi.ajp.2015.15060770
  12. Tsai J, Thase ME, Mao Y, Ng-Mak D, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. CNS Spectr 2017;22:236-245. https://doi.org/10.1017/S1092852917000074
  13. Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. CNS Spectr 2017;22:228-235. https://doi.org/10.1017/S1092852917000232
  14. Sramek J, Loebel A, Murphy M, Mao Y, Pikalov A, Cutler NR. Lurasidone in post-menopausal females with major depressive disorder with mixed features: post-hoc analysis of a placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2017;78:12-17. https://doi.org/10.1016/j.pnpbp.2017.05.002
  15. Goldberg J, Mao Y, Siu C, Tsai J, Pikalov A, Calabrese J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response? Neuropsychopharmacology 2016;41:S515-S516.
  16. Patkar AA, Pae CU, Vohringer PA, Mauer S, Narasimhan M, Dalley S, et al. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. J Clin Psychopharmacol 2015;35:319-323. https://doi.org/10.1097/JCP.0000000000000323
  17. Suppes T, Ostacher M. Mixed features in major depressive disorder: diagnoses and treatments. CNS Spectr 2017;22:155-160. https://doi.org/10.1017/S1092852917000256
  18. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry 2009;70:1424-1431. https://doi.org/10.4088/JCP.08m04772gre
  19. Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord 2014;164:57-62. https://doi.org/10.1016/j.jad.2014.04.003
  20. McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015;76:398-405. https://doi.org/10.4088/JCP.14m09410
  21. Patkar A, Gilmer W, Pae CU, Vohringer PA, Ziffra M, Pirok E, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One 2012;7:e34757. https://doi.org/10.1371/journal.pone.0034757
  22. Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, Ghaemi SN. Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. Pharmacopsychiatry 2012;45:152-155. https://doi.org/10.1055/s-0031-1297984
  23. Muralidharan K, Ali M, Silveira LE, Bond DJ, Fountoulakis KN, Lam RW, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials. J Affect Disord 2013;150:408-414. https://doi.org/10.1016/j.jad.2013.04.032
  24. Nelson C, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features: effect of baseline depression severity on clinical outcome. Eur Neuropsychopharmacol 2016;26(Suppl):S400-S401. https://doi.org/10.1016/S0924-977X(16)31360-8
  25. Pikalov A, Goldberg J, Mao Y, Siu C, Tsai J, Calabrese J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response? Eur Psychiatry 2017;41 Suppl:S243.
  26. Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, et al. Guidelines for the recognition and management of mixed depression. CNS Spectr 2017;22:203-219. https://doi.org/10.1017/S1092852917000165
  27. Pae CU, Vohringer PA, Holtzman NS, Thommi SB, Patkar A, Gilmer W, et al. Mixed depression: a study of its phenomenology and relation to treatment response. J Affect Disord 2012;136:1059-1061. https://doi.org/10.1016/j.jad.2011.11.024
  28. Seo JS, Bahk WM, Wang HR, Woo YS, Park YM, Jeong JH, et al. Korean Medication Algorithm for Depressive Disorders 2017: third revision. Clin Psychopharmacol Neurosci 2018;16:67-87. https://doi.org/10.9758/cpn.2018.16.1.67
  29. Wang HR, Bahk WM, Seo JS, Woo YS, Park YM, Jeong JH, et al. Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines. Clin Psychopharmacol Neurosci 2017;15:199-209. https://doi.org/10.9758/cpn.2017.15.3.199
  30. McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry 2017;78:703-713. https://doi.org/10.4088/JCP.16cs10885
  31. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2009;70:1540-1547. https://doi.org/10.4088/JCP.08m04895yel

Cited by

  1. Diagnostic Issues of Depressive Disorders from Kraepelinian Dualism to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition vol.16, pp.9, 2018, https://doi.org/10.30773/pi.2019.09.07
  2. Depression Preceding Diagnosis of Bipolar Disorder vol.11, pp.None, 2018, https://doi.org/10.3389/fpsyt.2020.00500
  3. The Korean Medication Algorithm Project for Bipolar Disorder (KMAP‐BP): Changes in preferred treatment strategies and medications over 16 years and five editions vol.22, pp.5, 2018, https://doi.org/10.1111/bdi.12902
  4. Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy vol.12, pp.None, 2018, https://doi.org/10.3389/fpsyt.2021.623684
  5. Electroconvulsive Therapy in Mania: A Review of 80 Years of Clinical Experience vol.178, pp.3, 2018, https://doi.org/10.1176/appi.ajp.2020.20030238
  6. Diagnosing and treating major depressive episodes that lie along the mood disorders spectrum: focus on depression with mixed features vol.26, pp.2, 2018, https://doi.org/10.1017/s1092852921000262
  7. Ecological momentary assessment of mood and movement with bipolar disorder over time: Participant recruitment and efficacy of study methods vol.30, pp.4, 2018, https://doi.org/10.1002/mpr.1895